急性与亚急性无并发症B型主动脉夹层:腔内治疗与药物治疗的荟萃分析
该系统综述与荟萃分析比较了胸主动脉腔内修复(TEVAR)与最佳药物治疗(BMT)在急性及亚急性无并发症B型主动脉夹层(uTBAD)中的围术期及远期结局。结果显示两组住院死亡率与早期再干预无显著差异,BMT早期卒中风险更低,但远期全因死亡及主动脉相关死亡风险显著高于TEVAR。
要点
- TEVAR与BMT在住院死亡率及早期再干预方面无统计学显著差异。
- BMT组早期卒中风险显著低于TEVAR组(OR 0.64)。
- BMT组远期全因死亡及主动脉相关死亡风险显著高于TEVAR组。
核心结论
- 由于合适研究的数量和质量有限,TEVAR在急性/亚急性uTBAD管理中的获益仍不确定,需进一步研究明确哪些夹层可从预防性治疗中获益。
研究设计与样本
- 系统综述与荟萃分析,纳入观察性研究和随机对照试验(RCT),遵循PRISMA指南并注册(CRD42018094607)。
主要发现
- TEVAR与BMT的住院死亡率无显著差异(RD 0.01,95% CI -0.01-0.02,p = .46)。
- TEVAR与BMT的早期再干预(TEVAR:RD 0.02,95% CI -0.01-0.04,p = .19;手术:RD 0.00,95% CI -0.01-0.01,p = 1.0)无显著差异。
- BMT与早期卒中风险显著降低相关(OR 0.64,95% CI 0.48-0.85,p = .002)。
- BMT的远期全因死亡风险(HR 1.54,95% CI 1.27-1.86,p < .001)和主动脉相关死亡风险(HR 2.71,95% CI 1.49-4.94,p = .001)显著高于TEVAR。
- 未找到适合荟萃分析的远期主动脉再干预数据。
临床怎么用
- 对于急性/亚急性uTBAD,TEVAR与BMT的早期死亡和再干预风险相当,但BMT早期卒中风险更低。
- BMT远期全因死亡及主动脉相关死亡风险较高,选择治疗策略时需权衡早期卒中与远期死亡风险。
局限性
- 纳入研究的数量和质量有限,可能影响结论的可靠性。
- 缺乏远期主动脉再干预的合适数据,无法进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was to compare peri-operative and late outcomes of patients with acute and subacute uncomplicated type B aortic dissection (uTBAD) treated by thoracic endovascular aortic repair (TEVAR) or best medical therapy (BMT). METHODS: This was a Systematic review and meta-analysis of observational studies and randomised controlled trials (RCTs). The review was undertaken according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered with the International Prospective Register of Systematic Reviews (number: CRD42018094607). Multiple electronic databases were searched to identify relevant articles. The methodological quality of the included studies was assessed. The primary outcome measures were early mortality and re-intervention, late all cause and aorta related mortality, and re-intervention. Meta-analysis was used to produce pooled odds ratios (OR) or risk difference (RD) for peri-operative outcomes. Random effects models were applied. For late outcomes a time to event meta-analysis was conducted using the inverse variance model, reporting the results as hazard ratios (HR). RESULTS: Eight original articles from six studies encompassing 14 706 patients (1 066 TEVARs) were eligible for inclusion. There were no statistically significant differences between TEVAR and BMT with regards to inpatient mortality (RD 0.01, 95% CI -0.01-0.02, p = .46), early re-intervention by TEVAR (RD 0.02, 95% CI -0.01-0.04, p = .19) or surgery (RD 0.00, 95% CI -0.01-0.01, p = 1.0). BMT was associated with a significantly lower risk of early stroke (OR 0.64, 95% CI 0.48-0.85, p = .002), whereas the risk of late all cause (HR 1.54, 95% CI 1.27-1.86, p < .001) and aorta related mortality (HR 2.71, 95% CI 1.49-4.94, p = .001) was significantly higher than with TEVAR. No suitable data regarding late aortic re-intervention was found for meta-analysis. CONCLUSION: Given the limited number and quality of suitable studies it remains uncertain whether TEVAR is beneficial in the management of acute/subacute uTBAD. Further research is required to understand which dissections would benefit from pre-emptive treatment.
引用
- Hossack M, Patel S, Gambardella I, et al. Endovascular vs. Medical Management for Uncomplicated Acute and Sub-acute Type B Aortic Dissection: A Meta-analysis. Eur J Vasc Endovasc Surg. 2019. PMID: 31899101. doi:10.1016/j.ejvs.2019.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。